Page 36 - Haematologica Vol. 107 - September 2022

REVIEW ARTICLE - ITP: diagnosis and second-line treatment J.B. Bussel and C.A. Garcia
37. Bussel J, Kulasekararaj A, Cooper N, et al. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019;56(4):262-278.
38. Liu ZJ, Deschmann E, Ramsey HE, et al. Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro. Blood Adv. 2022;6(1):13-27.
39. Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018;93(1):58-64.
40. Lakhwani S, Perera M, Fernandez-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372-377.
41. Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Am J Hematol. 2021;96(10):E373-E376.
42. Piatek CI, Jamieson B, Vredenburg M. Characterization of thromboembolic events occurring during the avatrombopag immune thrombocytopenia (ITP) clinical development program. Blood. 2020;136(Suppl 1):39.
43. Pavord S, Thachil J, Hunt BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020;189(6):1038-1043.
44. American Hematology Scoiety. COVID-19 and ITP. 2022 5/31/2022. Available from: https://www.hematology.org/covid- 19/covid-19-and-itp. (last accessed March 2022)
45. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930.
46. Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood. 2019;133(19):2027-2030.
47. Strich JR, Tian X, Samour M, et al. Fostamatinib for the treatment of hospitalized adults with COVD-19 A [sic] randomized trial. Clin Infect Dis. 2021 Sep 1. [Epub ahead of print]
48. Mageau A, Terriou L, Ebbo M, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022;97(1):10-17.
49. Theilacker C, Ludewig K, Serr A, et al. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis. 2016;62(7):871-878.
50. Tahir F, Ahmed J, Malik F. Post-splenectomy sepsis: a review of the literature. Cureus. 2020;12(2):e6898.
51. Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ. 2005;331(7514):417-418.
52. Feng Q, Tamimi R, Mu Y, Pen J, Bussel JB. Splenectomy results in venous thromboembolic events in women: a Nurses Health Study. Blood. 2021;138(Suppl 1):3163.
53. Rodeghiero F, Marranconi E. Management of immune thrombocytopenia in women: current standards and special considerations. Expert Rev Hematol. 2020;13(2):175-185.
54. Upson K, Harmon QE, Heffron R, et al. Depot medroxyprogesterone acetate use and blood lead levels in a cohort of young women. Environ Health Perspect. 2020;128(11):117004.
55. Bussel JB, Druzin ML, Cines DB, Samuels P. Thrombocytopenia in pregnancy. Lancet. 1991;337(8735):251.
56. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993;329(20):1463-1466.
57. Boehlen F, Hohlfeld P, Extermann P, Perneger TV, de Moerloose P. Platelet count at term pregnancy: a reappraisal of the threshold. Obstet Gynecol. 2000;95(1):29-33.
58. Sainio S, Kekomaki R, Riikonen S, Teramo K. Maternal thrombocytopenia at term: a population-based study. Acta Obstet Gynecol Scand. 2000;79(9):744-749.
59. Khanuja K, Levy AT, McLaren RA Jr, Berghella V. Pre- and postpregnancy platelet counts: evaluating accuracy of gestational thrombocytopenia and immune thrombocytopenia purpura diagnoses. Am J Obstet Gynecol MFM. 2022;4(3):100606.
60. Dockree S, Shine B, Impey L, Mackillop L, Randeva H, Vatish M. Improving diagnostic accuracy in pregnancy with individualised, gestational age-specific reference intervals. Clin Chim Acta. 2022;527:56-60.
61. Chen Q, Liu F, Sun X, Wang C, et al. High level of estradiol induces megakaryocyte apoptosis and impairs proplatelete formation via MST1-FOXO1 axis during pregnancy in patients with immune thrombocytopenia. European Hematology Association; 2021 06/09/2021. EHA Library; (no. 324706). Available from: https://library.ehaweb.org/eha/2021/eha2021- virtual-congress/324706/qi.chen.high.level.of.estradiol.induces.m egakaryocyte.apoptosis.and.impairs.html?f=listing%3D3%2Abro wseby%3D8%2Asortby%3D1%2Amedia%3D1. (last accessed August 2021)
62. Peitsidis P, Kadir RA. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother. 2011;12(4):503-516.
63. Mantero F, Opocher G, Armanini D, Filipponi S. 11 Beta- hydroxylase deficiency. J Endocrinol Invest. 1995;18(7):545-549.
64. Sun D, Shehata N, Ye XY, et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood. 2016;128(10):1329-1335.
65. Lakkaraja M, Berkowitz RL, Vinograd CA, et al. Omission of fetal sampling in treatment of subsequent pregnancies in fetal- neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2016;215(4):471.e1-9.
66. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-1506.
67. Michel M, Novoa MV, Bussel JB. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol. 2003;123(1):142-146.
68. Natekar A, Pupco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011;57(12):1401-1402.
69. Sukenik-Halevy R, Ellis MH, Fejgin MD. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008;63(3):182-188.
70. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051-1055.
71. Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008;7(3):219-222.
72. Kong Z, Qin P, Xiao S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097-1103.
73. Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood. 2020;136(26):3056-3061.
74. Bussel JB, Cooper N, Lawrence T, et al. Surveillance program of
Haematologica | 107 September 2022
2035